

# Nocturia - Market Insight, Epidemiology and Market Forecast - 2028

29% of the USA population over 45 years old wake to urinate once or more per night; the estimates were 25.3 million men and 33.2 million women with recurrent nocturia.



Albany, Feb 5, 2019 ([IssueWire.com](http://www.IssueWire.com)) - [Nocturia - Market Insight, Epidemiology and Market Forecast - 2028](#)

**29% of the USA population over 45 years old wake to urinate once or more per night; the estimates were 25.3 million men and 33.2 million women with recurrent nocturia.**

- Nocturia is an extremely common condition, affecting both men and women of all ages. Almost 69% of men and 76% of women (aged  $\geq 40$  years) in the United States and United Kingdom reported  $\geq 1$  nocturnal voids.
- In 2012, the proportion of men aged 20 to 30 years reporting  $\geq 2$  voids per night was 2% to 17%, rising to 29% to 59% in men aged 70 to 80 years.
- The prevalence of nocturia increases with age. More than 70% of people aged 70 years and over are affected. A substantial proportion of younger adults are affected with up to 30% of those aged 20–40 years voiding at least once per night. Younger sufferers are more likely to be female, however, prevalence is similar in both genders in older patients.

(Albany, US) DelveInsight launched a new report on [Nocturia - Market Insight, Epidemiology and Market Forecast - 2028](#)

[Request for sample pages](#)

[Key topics covered](#)

- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Nocturia market
- Organize sales and marketing efforts by identifying the best opportunities for Nocturia market
- To understand the future market competition in the Nocturia market.

*“The prevalence of nocturia in the community increases with age, with rates of 29%-59% for men aged 70-80 years and of 28%-62% for women of the same age ( $\geq 2$  voids per night) [2017]”*

The goals of Nocturia therapy are not specifically aimed at reducing the frequency of nocturia, but also

to improve the health-related quality of life (HRQoL), degree of bother, and optimize co-morbidities contributing to nocturia. The treatment strategies for nocturia focus on minimizing the symptoms of nocturnal voiding episodes to improve the quality of life.

Although various drug therapies are available for the treatment of nocturia, high doses of these drugs may cause various adverse effects. Complex pathophysiology of the disease, high cost of treatment associated with nocturia are some of the limitations of existing therapy for the nocturia market.

So, there is a high unmet need of novel therapies that can overcome the limitations of existing drugs. Companies are developing the combination therapies as well as extended release formulations for the treatment of nocturia. Rising number of patients with Nocturia, raising awareness, and increasing research and development activities are some of the factors which are expected to contribute towards the market growth during the forecast period (2019-2028). Additionally, due to the lack of therapies which effectively stop or slow the disease progression, a large opportunity exists for the development and launch of novel therapies.

### **Companies covered**

- **Allergan**
- **Ferring Pharmaceuticals**

### **And many others**

#### **Drugs covered**

- **Noctiva**
- **Nocdurna**

### **And many others**

### **Table of contents**

- **1. Report Introduction**
- **2. Nocturia Market Overview at a Glance**
- **3. Disease Background and Overview: Nocturia**
- **4. Epidemiology and Patient Population**
  - **4.1. Key Findings**
  - **4.2. Total Prevalent/ Incident Patient Population of Nocturia in 7MM**
  - **4.3. Total Prevalent Patient Population of Nocturia in 7MM – By Countries**
- **5. Epidemiology of Nocturia by Countries**
  - **5.1. United States**
  - **5.2. EU5**
  - **5.3. Assumptions and Rationale**
  - **5.4. Germany**
  - **5.5. France**
  - **5.6. Italy**
  - **5.7. Spain**
  - **5.8. United Kingdom**
  - **5.9. Japan**
    - **5.9.1. Assumptions and Rationale**

- 5.9.2. Prevalent/Incident Cases of the Nocturia
- 5.9.3. Sub-Type Specific cases of the Nocturia \*
- 5.9.4. Sex-Specific Cases of the Nocturia \*
- 5.9.5. Diagnosed Cases of the Nocturia
- 5.9.6. Treatable Cases of the Nocturia
- 6. Current Treatment & Medical practices
  - 6.1. Treatment Algorithm
  - 6.2. Treatment Guidelines
- 7. Unmet Needs of the Nocturia
- 8. Marketed Therapies
  - 8.1. Drug A: Company 1
  - 8.2. Drug B: Company 2
- 9. Pipeline Therapies – At a glance
- 10. Key Cross Competition
- 11. Emerging Therapies for Nocturia
  - 11.1. Drug C: Company 3
  - 11.2. Drug D: Company 4
- 12. Nocturia : 7MM Market Analysis
- 13. Nocturia : Country-Wise Market Analysis
  - 13.1. United States
  - 13.2. EU-5
    - 13.2.1. Germany
    - 13.2.2. France
    - 13.2.3. Italy
    - 13.2.4. Spain
    - 13.2.5. United Kingdom
  - 13.3. Japan
- 14. Market Drivers
- 15. Market Barriers
- 16. Appendix
- 17. Report Methodology
  - 17.1. Sources
- 18. DelveInsight Capabilities
- 19. Disclaimer

## About [DelveInsight](#)

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

### Contact us:

**Shruti Thakur**

[info@delveinsight.com](mailto:info@delveinsight.com)

**+919650213330**

**SOURCE DelveInsight****Media Contact**

Delveinsight Business Reserarch LLP

info@delveinsight.com

304 S. Jones Blvd #2432, Las Vegas NV 89107

Source : DelveInsight

See on IssueWire : <https://www.issuewire.com/nocturia-market-insight-epidemiology-and-market-forecast-2028-1624624932472155>